As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS

BiTEs Bring New Side Effects To Solid Tumor Setting

Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.

Health care and medical technology services concept. Medical worker using data virtual with health care icons, medical technology background, health insurance business.
Bispecific T-cell engagers require new safety protocols in treating solid tumors • Source: Shutterstock

Amgen, Inc.’s Imdelltra (tarlatamab) for extensive-stage small cell lung cancer (ES-SCLC) is one of only two bispecific T-cell engagers (BiTEs) approved in the US to treat solid tumors. As additional DLL3-targeting BiTEs near the market, those drugs may benefit from doctors’ earlier experience learning to manage adverse events for BiTEs and other T-cell recruiters – chiefly cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS)

More from Clinical Trials

More from R&D